Clopidogrel bisulfate NDC 55111-196

NDC codes

FDA NDC Directory

Product NDC (as listed)55111-196Labeler and product segments. Claims need a package NDC.

Product NDC at billing width55111-0196Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
55111-196-05	55111019605	500 TABLET, FILM COATED in 1 BOTTLE (55111-196-05)Marketed from May 17, 2012
55111-196-30	55111019630	30 TABLET, FILM COATED in 1 BOTTLE (55111-196-30)Marketed from May 17, 2012
55111-196-90	55111019690	90 TABLET, FILM COATED in 1 BOTTLE (55111-196-90)Marketed from May 17, 2012

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Clopidogrel bisulfate
Generic name (nonproprietary): clopidogrel bisulfate
Active ingredients: Clopidogrel bisulfate — 75 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Dr.Reddy's Laboratories Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076273
Marketing start: May 17, 2012
Marketing end: Dec 31, 2026
Other FDA classes: Cytochrome P450 2C8 Inhibitors (Mechanism)Decreased Platelet Aggregation (Physiologic effect)P2Y12 Receptor Antagonists (Mechanism)
Identifiers: Product ID 55111-196_7fbef39d-2dec-fb75-2e25-b6a3b2d656e2SPL ID 7fbef39d-2dec-fb75-2e25-b6a3b2d656e2SPL set ID b5aa951f-72de-bea1-98a2-a4085c64a361RxCUI 309362UNII 08I79HTP27
Pharmacologic class: P2Y12 Platelet Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N455111019605 followed by a unit qualifier and the quantity

Package 55111-0196-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 28, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Clopidogrel tablets are a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke. (1.1) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.1) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.2) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel tablets are indicated to reduce the rate of myo…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 076273

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 076273
Product	Strength	Form · route	Labeler	Product NDC
Clopidogrel bisulfate	Clopidogrel bisulfate 75 mg/1	Tablet, Film coatedOral	Quallent Pharmaceuticals Health LLC	82009-021